Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer

Clinical Colorectal Cancer

Volumn 9, Issue 1, 2010, Pages 55-58

  Gamboa, Eric O ^a   Rehmus, Esther H ^b,c   Haller, Nairmeen ^b,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b AKRON GENERAL MEDICAL CENTER   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Arterial thromboembolism; FGSIS; Vascular endothelial growth factor; Wound healing complications

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; VASCULOTROPIN;

AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; BACTEROIDES FRAGILIS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLORECTAL CANCER; DISEASE SEVERITY; ENTEROBACTER AEROGENES; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; FOURNIER GANGRENE; HISTOPATHOLOGY; HUMAN; MALE; METASTASIS; STAPHYLOCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 77149180098     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.008     Document Type: Article

References (15)

1. Jeong HJ, Park SC, Seo IY, et al. Prognostic factors in Fournier's gangrene. Int J Urol 2005; 12:1041-1044
2. Ayan F, Sunamak O, Paksoy SM, et al. Fournier's gangrene: a retrospective clinical study on forty-one patients. ANZ J Surg 2005; 75:1055-1058
3. Fukono K, Tsurumi H, Goto H, et al. Genital ulcers during treatment will all-trans retinoic acid for acute promyelocytic leukemia. Leuk Lymphoma 2003; 44:2009-2013
4. Naithani R, Kumar R, Mahapatra M. Fournier's gangrene and scrotal ulcerations during all-trans-retinoic acid therapy for acute promyelocytic leukemia. Pediatr Blood Cancer 2008; 51:303-304
5. Korkut M, Icoz G, Dayangac M, et al. Outcome analysis in patients with Fournier's gangrene: report of 45 cases. Dis Colon Rectum 2003; 46:649-652
6. Yeniyol CO, Suelozgen T, Arslan M, et al. Fournier's gangrene: experience with 25 patients and use of Fournier's gangrene severity index score. Urology 2004; 64:218-222
7. Laor E, Palmer LS, Tolia BM, et al. Outcome prediction in patients with Fournier's gangrene. J Urol 1995; 154:89-92.
8. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9(Suppl 1):2-10. (Pubitemid 38747842)
9. Hurwitz HI, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342
10. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697-3705
11. Gressett SM, Shah SR. Intricacies of bevacizumab induced toxicities and their management. Ann Pharmacother 2009; 43:490-501.
12. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173-180
13. Skillings JR, Johnson DH, Miller K, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 2005; 23:196s (abstract 3019).
14. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 2004; 22:1198.
15. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 2006; 63:334-337